Evaluation of Renal Protection by Impidapril and Irbesartan in Patients with Essential Hypertensio
Phase 3
- Conditions
- Essential Hypertension
- Registration Number
- JPRN-UMIN000002430
- Lead Sponsor
- Medicine and Bioregulatory Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
patients with malignancy renal failure (serum creatinine more than 3mg/dl)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method clinic and home blood pressure, body weight, waist circumference, albuminuria
- Secondary Outcome Measures
Name Time Method urinary 8OHdG, urinary NOx, adiponectin, plasma glucose, HbA1c, BNP